Recro Pharma Inc expected to post a loss of 25  cents a share - Earnings Preview

Societal CDMO

05/05/2021 03:01

* Recro Pharma Inc  REPH.OQ   REPH.O  is expected to show a fall
in quarterly revenue when it reports results on May 6.
* The Malvern, Pennsylvania-based company is expected to report 
 a 24.5% decrease in revenue to $16.431 million from $21.78
million a year ago, according to the mean estimate from 2
analysts, based on Refinitiv data.
​* Refinitiv's mean analyst estimate for Recro Pharma Inc is for
a loss of 25 cents per share. For the same quarter last year,
the company reported a loss of 33 cents per share.
* The current average analyst rating on the shares is "strong
buy" and the breakdown of recommendations is 2 "strong buy" or
"buy," no "hold" and no "sell" or "strong sell." 
* The mean earnings estimate of analysts was unchanged in the
last three months. ​
* Wall Street's median 12-month price target for Recro Pharma
Inc is $5.5​, about 52.9% above​ its last closing price
of $2.59. ​​​
* Previous quarterly performance (using preferred earnings
measure in US dollars). ​
 QUARTER       STARMINE    REFINITIV  ACTUAL    BEAT,   SURPRI
 ENDING        SMARTESTIM  IBES                 MET,    SE %
               ATE®        ESTIMATE             MISSED  
 Dec. 31 2020  -0.25       -0.22      -0.48     Missed  -118.2
 Sep. 30 2020  -0.21       -0.20      -0.09     Beat    56.1
 Jun. 30 2020  -0.17       -0.16      -0.25     Missed  -56.2​
 Mar. 31 2020  -0.02       -0.03      -0.33     Missed  -890.1
 Dec.          -0.22​      -0.25      0.61      Beat    341.6​
 31​ 2019​                                              
 Sep. 30 2019  -0.11       -0.21      -0.19     Beat    7.8​
 Jun. 30 2019  -0.40       -0.42      -0.13     Beat    69
 Mar. 31 2019  -0.74       -1.06      -0.09     Beat    91.5
 This summary was machine generated May 5 at 02:01 GMT.  All
figures in US dollars unless otherwise stated